SCHEMBL6489261

SCHEMBL6489261

CC(C)c1ccc(-c2ccc(F)cc2)c(C(=O)O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
EIF4E P06730 1/20 0.46
PRKAB2 O43741 1/20 0.46
PRKAG1 P54619 1/20 0.46
PRKAA2 P54646 1/20 0.46
PRKAA1 Q13131 1/20 0.46
PRKAG3 Q9UGI9 1/20 0.46
PRKAG2 Q9UGJ0 1/20 0.46
PRKAB1 Q9Y478 1/20 0.46
DHODH Q02127 2/20 0.45
GPR35 Q9HC97 2/20 0.44
CYP2C19 P33261 3/20 0.43
CYP2C9 P11712 2/20 0.43
APP P05067 2/20 0.43
CYP3A4 P08684 1/20 0.43
MEN1 O00255 3/20 0.43
PTGS1 P23219 3/20 0.43
KMT2A Q03164 3/20 0.43
AKR1C3 P42330 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20509052 0.86 SCN9A (0.44) MEN1KMT2ASLC6A4SLC6A3
SCHEMBL6490473 0.86 AKR1C2 (0.49) HSD17B10SMN1; SMN2PRKAB2PRKAG1PRKAA2
SCHEMBL6499038 0.85 FOLH1 (0.53) HSD17B10SMN1; SMN2PRKAB2PRKAG1PRKAA2
SCHEMBL6488790 0.84 AKR1C3 (0.58) HSD17B10SMN1; SMN2PRKAB2PRKAG1PRKAA2
SCHEMBL6498591 0.81 HSD17B10 (0.58) HSD17B10SMN1; SMN2EIF4EDHODHGPR35
SCHEMBL31586500 0.81 HSD17B10 (0.58) HSD17B10SMN1; SMN2EIF4EDHODHGPR35
SCHEMBL29898486 0.80 PRKAB2 (0.56) HSD17B10SMN1; SMN2PRKAB2PRKAG1PRKAA2
SCHEMBL7245003 0.79 PRKAB2 (0.50) HSD17B10SMN1; SMN2EIF4EPRKAB2PRKAG1
SCHEMBL6499746 0.79 ALDH1A1 (0.59) HSD17B10SMN1; SMN2DHODHCYP2C19CYP2C9
SCHEMBL6492370 0.79 HSD17B10 (0.51) HSD17B10SMN1; SMN2EIF4EDHODHGPR35

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 HSD17B10 901/4885SMN1; SMN2 1921/4885EIF4E 4728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.